The proposed CIRM ASCEND Center provides cutting-edge organoid-based services, offering consultation, optimized protocols, and genomic analysis. We also offer comprehensive training, workshops, and access to data, empowering researchers across California…
This project enhances stem cell access, scalability, and collaboration. It offers characterized hPSC lines, CRISPR editing, and differentiation on automated platforms accelerating progress in biology, disease research, and regenerative medicine.…
Our broad objective is to expand access to equipment, services, and training within our areas of excellence. Through knowledge sharing and collaboration, we aim to add value to the CIRM…
The Cal Poly Humboldt Shared Resource Laboratory for Human Stem Cell-Based Modeling (SRL-hSC) will provide modeling resources and educational offerings to researchers, educators, and students in our rural and remote…
The areas of focus for our SRL will include induced pluripotent stem cell generation and characterization, cell differentiation and generation of a microvascular tissue model and in vivo models. Our…
Use of stem cells in human disease modeling has reached a broader scientific audience of underserved, marginalized communities. Researchers/scholars have comprehensive training in iPSC generation, genetic modification, and differentiation techniques…
Our Shared Resource Laboratory will expand access to stem cell-derived models to support research and educational programs with two main goals: democratize access to state-of-the-art models and technology among a…
Research Objective We will build a foundational model and experimental platform to catalog all genes that promote and protect against PAH, with the potential to extend to many other developmental…
Research Objective We will generate insights about mechanisms by which 𝛼-synuclein leads to neurodegeneration of the forebrain and substantia nigra, regions affected in Lewy body dementias and Parkinson disease. Impact…
Research Objective The goal of our project is to generate cells for replacement therapy in patients that have reduced ability to trigger the immune response in the recipient and therefore…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
